The Biotech Startups Podcast

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs. Mati traces his path from juggling a minister's bureau with Israeli law school to joining Teva as an intern with no private-sector experience, then learning a 45,000-person org from the chart up — until Teva's financial crisis handed him the mandate to build the innovation program that became AION Labs.

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs—a first-of-its-kind AI venture studio backed by Teva, Pfizer, AstraZeneca, Merck, and Amazon Web Services. Before AION Labs, Mati spent six years in the IDF, ran a minister's bureau, and rose from legal intern to global legal COO at Teva over more than a decade. Part one covers the formative years: moving from Columbus, Ohio to Jerusalem at 12, extending military service by three years, and the two teachers who handed him D's and changed how he works.

In part four, Alex Telford, founder of Convoke, covers the platform architecture and roadmap. He walks through Convoke's modular system—building validated structured datasets from trial registries, regulatory filings, and patents, then stitching them with workflow tools for competitive intelligence and document generation. He breaks down how pharma and biotech customers engage differently, why an "everything app" is a trap, and how Convoke is moving from reactive data storage toward proactive, predictive intelligence.

In this episode, Jon Chee sits down with Alex Telford, founder of Convoke, to examine why large pharma resists AI transformation. Drawing on seven years at Charles River Associates, Alex maps the coordination tax of siloed orgs, the tacit knowledge lost when experts retire, and why software efficiency is the wrong axis to compete on. His frame: factory electrification — the gains don't arrive until you redesign the whole org around the technology.

In this episode of The Biotech Startups Podcast, Jon Chee sits down with Alex Telford, founder of Convoke, who spent nearly seven years in biopharma strategy consulting before what he calls "AI psychosis" set him on a different path. Alex traces the arc from biochemistry at Bristol and synthetic biology at UCL to discovering consulting existed only after graduating, joining a boutique Swiss firm two weeks before it was acquired, and learning one core lesson: clients want a recommendation to push back on, not a data dump.